BRPI0513136A - composição farmacêutica contendo fragmentos de polipeptìdeo das serralisinas - Google Patents

composição farmacêutica contendo fragmentos de polipeptìdeo das serralisinas

Info

Publication number
BRPI0513136A
BRPI0513136A BRPI0513136-7A BRPI0513136A BRPI0513136A BR PI0513136 A BRPI0513136 A BR PI0513136A BR PI0513136 A BRPI0513136 A BR PI0513136A BR PI0513136 A BRPI0513136 A BR PI0513136A
Authority
BR
Brazil
Prior art keywords
serralisin
polypeptide fragments
composition
pharmaceutical composition
composition containing
Prior art date
Application number
BRPI0513136-7A
Other languages
English (en)
Inventor
Maria Del Carmen Abrahan Perez
Jesus Reyes Gonzalez
Gloria Veliz Rios
Eduardo Martinez Diaz
Caridad Anais Gasmuri Gonzalez
Jose Garcia Suarez
Monica Bequet Romero
Luis Javier Gonzalez Lopez
Lila Rosa Castellanos Serra
Manuel Selman-Housein Sosa
Raul Gomez Riera
Jorge Victor Gavilondo Cowley
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of BRPI0513136A publication Critical patent/BRPI0513136A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/265—Enterobacter (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

COMPOSIçãO FARMACêUTICA CONTENDO FRAGMENTOS DE POLIPEPTìDEO DAS SERRALISINAS. A presente invenção refere-se a uma composição capaz de inibir o crescimento de células tumorais de diferentes origens histológicas e de células endoteliais ativadas. Os componentes das ditas composições são fragmentos de polipeptídeo das serralisinas, correspondendo ao fragmento C-terminal, da metionina interna até a extremidade da molécula, que poderiam ser combinados entre eles e opcionalmente com as prodigiosinas que potencializam os efeitos antitumorais da composição. As prodigiosinas na composição poderiam estar em uma concentração de 0,1-100 nM. A ação antiproliferativa desta composição é mediada através de mecanismo apoptótico. Sua administração "in vivo" tem efeito antitumoral, antiangiogênico e protetor contra tumores malignos.
BRPI0513136-7A 2004-07-08 2005-07-05 composição farmacêutica contendo fragmentos de polipeptìdeo das serralisinas BRPI0513136A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20040147A CU23475A1 (es) 2004-07-08 2004-07-08 Composición farmacéutica conteniendo fragmentos polipeptídicos de serralisinas
PCT/CU2005/000003 WO2006005268A2 (es) 2004-07-08 2005-07-05 Composición farmacéutica conteniendo fragmentos polipéptidicos de serralisinas

Publications (1)

Publication Number Publication Date
BRPI0513136A true BRPI0513136A (pt) 2008-04-29

Family

ID=40259088

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513136-7A BRPI0513136A (pt) 2004-07-08 2005-07-05 composição farmacêutica contendo fragmentos de polipeptìdeo das serralisinas

Country Status (22)

Country Link
US (1) US8076297B2 (pt)
EP (1) EP1787653B1 (pt)
JP (1) JP4914350B2 (pt)
KR (1) KR101365056B1 (pt)
AR (1) AR050255A1 (pt)
AU (1) AU2005262159B2 (pt)
BR (1) BRPI0513136A (pt)
CA (1) CA2572984C (pt)
CU (1) CU23475A1 (pt)
CY (1) CY1114201T1 (pt)
DK (1) DK1787653T3 (pt)
ES (1) ES2389126T3 (pt)
HR (1) HRP20120682T1 (pt)
MX (1) MX2007000339A (pt)
MY (1) MY150858A (pt)
PL (1) PL1787653T3 (pt)
PT (1) PT1787653E (pt)
RS (1) RS52448B (pt)
RU (1) RU2396274C2 (pt)
SI (1) SI1787653T1 (pt)
WO (1) WO2006005268A2 (pt)
ZA (1) ZA200700178B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5086093B2 (ja) * 2004-11-23 2012-11-28 ジモジェネティクス、インコーポレイテッド 組換え型ヒトｘｉｉｉ因子の精製
WO2008135873A1 (en) 2007-05-04 2008-11-13 Koninklijke Philips Electronics, N.V. Hybrid mr/pet with correction for radiation absorption by mr coil
CU23950B1 (es) 2011-03-21 2013-10-29 Ct De Ingeniería Genética Y Biotecnología Péptidos cíclicos con actividad antineoplásica y antiangiogénica
TWI746449B (zh) * 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法
CN109295041A (zh) * 2018-10-10 2019-02-01 宁波希诺亚海洋生物科技有限公司 具有舍雷肽酶活性的多肽及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58134991A (ja) * 1981-12-28 1983-08-11 Takeda Chem Ind Ltd セラチオペプチタ−ゼの安定化法
JP2611206B2 (ja) * 1985-11-15 1997-05-21 武田薬品工業株式会社 遺伝子およびその利用方法
KR100252197B1 (ko) * 1997-09-20 2000-04-15 박호군 세라시아 마르세센스 균주의 배양액으로 부터 분리한 면역억제제용 프로디지오신
US20040185566A1 (en) 2003-03-19 2004-09-23 Peter Salamone Polypeptides toxic to nematodes and methods of use

Also Published As

Publication number Publication date
EP1787653B1 (en) 2012-06-06
AR050255A1 (es) 2006-10-11
PT1787653E (pt) 2012-09-06
MX2007000339A (es) 2007-03-12
ES2389126T3 (es) 2012-10-23
ZA200700178B (en) 2008-06-25
RS52448B (en) 2013-02-28
CA2572984C (en) 2014-12-09
PL1787653T3 (pl) 2012-11-30
JP4914350B2 (ja) 2012-04-11
HRP20120682T1 (hr) 2012-09-30
AU2005262159A1 (en) 2006-01-19
CY1114201T1 (el) 2016-08-31
CA2572984A1 (en) 2006-01-19
CU23475A1 (es) 2009-12-17
JP2008505129A (ja) 2008-02-21
SI1787653T1 (sl) 2012-10-30
WO2006005268A2 (es) 2006-01-19
RU2396274C2 (ru) 2010-08-10
AU2005262159B2 (en) 2011-08-18
RU2007104776A (ru) 2008-08-20
US8076297B2 (en) 2011-12-13
WO2006005268A3 (es) 2006-03-09
EP1787653A2 (en) 2007-05-23
US20110218138A1 (en) 2011-09-08
KR20070042542A (ko) 2007-04-23
KR101365056B1 (ko) 2014-02-21
DK1787653T3 (da) 2012-09-17
MY150858A (en) 2014-03-14

Similar Documents

Publication Publication Date Title
BRPI0513136A (pt) composição farmacêutica contendo fragmentos de polipeptìdeo das serralisinas
El et al. Octreotide and melatonin alleviate inflammasome-induced pyroptosis through inhibition of TLR4-NF-κB-NLRP3 pathway in hepatic ischemia/reperfusion injury
JP6602760B2 (ja) 選択的なｐｙｙ化合物及びその使用
BRPI0506741A (pt) glicosilação de peptìdeos ligados a o
BRPI0607326A2 (pt) composição de vacina, variante de peptìdeo de survivina, uso da referida composição, kit em partes e medicamento
NO20063522L (no) Gastrointestinal proliferativ faktor og anvendelser derav
EA200801275A1 (ru) Стабилизированные составы карбоната лантана
BRPI0410260A (pt) composição conjugada para medicamento
TW200630327A (en) Substituted phenylalkanoic acids
NO20053545L (no) Bindingsmidler som inhiberer myostatin.
UA96441C2 (ru) Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением
CY1107906T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου
EP2359864A3 (en) Targeting Vector-Phospholipid Conjugates
BRPI0620566B8 (pt) composição, composição para o tratamento profilático ou terapêutico de fibrose miocardial ou uma condição associada, composição para o tratamento profilático ou terapêutico de hipertensão, uso de uma composição, uso de vip ou de um fragmento do mesmo e uso de um vip
AR062775A1 (es) Composicion farmaceutica capaz de mejorar la actividad de glp -1 en un ser humano y su uso para preparar un medicamento
CU23432B6 (es) Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
PE20230819A1 (es) Composiciones y usos de glp-1
DE60314420D1 (de) Zusammensetzung auf grundlage substituierter 1,3-diphenylprop-2-en-1-on-derivaten, deren herstellung und verwendungen
BRPI0507177A (pt) agonistas (vpac2) do receptor peptìdico de ativação de adenilato ciclase pituitários (pacap) e seus métodos farmacológicos de uso
ITMI20051743A1 (it) Uso di coniugati della doxorubicina con albumina lattosaminata
ES2272555T3 (es) Composicion de estrogeno y otras hormonas con ascorbato, lisina, prol ina y otras sustancias.
BRPI0924061B8 (pt) composicão farmacêutica compreendendo uma proteína endorepellin
TW200733897A (en) Oral product for moistening skin
Elliyanti et al. An iodine treatments effect on cell proliferation rates of breast cancer cell lines; in vitro study
BR112022012499A2 (pt) Peptídeo, composição, métodos para tratar um paciente e para tratar uma doença, e, uso de um peptídeo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]